Rituximab therapy in Greek patients with rheumatoid arthritis.
OBJECTIVE
An open-label, prospective, uncontrolled study created to investigate clinical response, serological changes and side effects in Greek patients with rheumatoid arthritis (RA), after B-cell depletion with rituximab.


METHODS
Patients with high disease activity (disease activity score [DAS]-28 > 5.1) were selected for treatment with rituximab and received two infusions, 1 gr each, 2 weeks apart. Different disease parameters (visual analog scale, DAS-28, C-reactive protein [CRP], erythrocyte sedimentation rate, health assessment questionnaire, complement (C3), C4, rheumatoid factor [RF], anti-cyclic citrullinated peptide antibody [anti-CCP], swollen joint count, tender joint count, immunoglobulin M [IgM], IgG, IgA) were performed at base line, 2, 4, and 6 months post-treatment. Response was defined according to the American College of Rheumatology (ACR) criteria.


RESULTS
Seventeen patients received therapy. Treatment led to a reduction in various disease parameters. ACR20 was achieved in 41.11% of patients by week 8, 52.94% by week 16, and 82.35% by week 24. ACR50 was achieved in 5.88% by week 8, 41.17% by week 16, and 64.7% by week 24. ACR70 was achieved only by week 24 in 23.52% of patients. Statistical analysis has shown no differences in clinical response, between RF positive/negative patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with reduction of DAS-28 than with anti-CCP.


CONCLUSIONS
Rituximab is a well tolerated and effective treatment in RA. Response was not correlated to RF or anti-CCP positivity. Decline of RF was associated with clinical response and reduction of DAS-28 and CRP.
Tsiakalos
Aristotelis P
AP
Department of Pathophysiology, Medical School, National Univercity of Athens, Athens, Greece.
Avgoustidis
Nestor K
NK
Moutsopoulos
Haralampos M
HM
Rheumatology (Oxford). 2005 May;44 Suppl 2:ii3-ii7
15851524
Arthritis Rheum. 1992 Jul;35(7):749-55
1352449
Arthritis Res. 2000;2(2):126-31
11094422
Arthritis Rheum. 1998 May;41(5):778-99
9588729
Rheum Dis Clin North Am. 2001 May;27(2):335-53
11396096
Arthritis Rheum. 1992 Jul;35(7):745-8
1622412
BioDrugs. 2001;15(2):73-9
11437676
Arthritis Rheum. 2001 Sep;44(9):2029-37
11592364
N Engl J Med. 2004 Jun 17;350(25):2572-81
15201414
Curr Opin Rheumatol. 2003 May;15(3):246-52
12707577
Rheumatology (Oxford). 2001 Feb;40(2):205-11
11257159
Arthritis Rheum. 1984 Aug;27(8):864-72
6431998
Rheumatology (Oxford). 2000 Dec;39 Suppl 2:3-12
11276800
Autoimmun Rev. 2003 Mar;2(2):101-8
12848966
N Engl J Med. 2000 Nov 30;343(22):1594-602
11096166
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
Arthritis Rheum. 2004 Feb;50(2):353-63
14872476
Arthritis Rheum. 2002 Aug;46(8):2029-33
12209504
Ann Rheum Dis. 1993 Jul;52(7):517-9
8102226
Ann Intern Med. 2002 Jun 18;136(12):908-22
12069565
Arthritis Rheum. 1988 Mar;31(3):315-24
3358796
Ann Rheum Dis. 2005 Feb;64(2):246-52
15208177
J Immunol. 2001 Oct 15;167(8):4710-8
11591802
Scand J Rheumatol. 2003;32(1):12-8
12635940
Clin Exp Rheumatol. 1995 Sep-Oct;13 Suppl 12:S7-12
8846545
Immunology. 1999 Jun;97(2):188-96
10447731
Arthritis Res. 2000;2(2):90-4
11094418